Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Philadelphia, Pennsylvania

Phase 1 colorectal cancer trials in Philadelphia, PA

27 Phase 1 colorectal cancer studies are recruiting participants at sites in Philadelphia as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Philadelphia at a glance

  • 27 studies are recruiting at a site in Philadelphia.
  • By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (11).
  • By sponsor: industry (21), university, hospital or other (6).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Philadelphia

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Sidney Kimmel Cancer Center
    Registry record
    NCT07458347 · updated
  2. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Univ of Pennsylvania, Abramson Cancer Center
    Registry record
    NCT07020221 · updated
  3. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Fox Chase Cancer Center · University of Pennsylvania
    Registry record
    NCT07213791 · updated
  4. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Sydney Kimmel Cancer Center
    Registry record
    NCT06720987 · updated
  5. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Fox Chase Cancer Center
    Registry record
    NCT07542704 · updated
  6. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    University of Pennsylvania
    Registry record
    NCT03526835 · updated
  7. Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Fox Chase Cancer Center
    Study site
    Fox Chase Cancer Center
    Registry record
    NCT07167446 · updated
  8. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study sites
    Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization · University of Pennsylvania / Abramson Cancer Center
    Registry record
    NCT04657068 · updated
  9. GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Thomas Jefferson University
    Study site
    Sidney Kimmel Cancer Center at Thomas Jefferson University
    Registry record
    NCT07417488 · updated
  10. TCR1188-ABC Cells in KRAS-mutated Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Pennsylvania
    Study site
    University of Pennsylvania
    Registry record
    NCT07594067 · updated
  11. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    University of Pennsylvania, Perelman School of Medicine
    Registry record
    NCT05919264 · updated
  12. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Abramson Cancer Center of the University of Pennsylvania
    Registry record
    NCT04585750 · updated
  13. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #98
    Registry record
    NCT05176483 · updated
  14. A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07277270 · updated
  15. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Hospital of the University of Pennsylvania
    Registry record
    NCT06445062 · updated
  16. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    Thomas Jefferson University, Sidney Kimmel Cancer Center
    Registry record
    NCT07217171 · updated
  17. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study sites
    Children's Hospital of Philadelphia- Center for Childhood Cancer Research · University of Pennsylvania Abramson Cancer Center
    Registry record
    NCT03715933 · updated
  18. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Fate Therapeutics
    Study site
    Thomas Jefferson University, Sidney Kimmel Cancer Center
    Registry record
    NCT07216105 · updated
  19. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's Hospital of Philadelphia
    Registry record
    NCT04851119 · updated
  20. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    Thomas Jefferson University
    Registry record
    NCT07094113 · updated
  21. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Jefferson University Hospitals
    Registry record
    NCT06179160 · updated
  22. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Sidney Kimmel Cancer Center at Thomas Jefferson University
    Registry record
    NCT03947385 · updated
  23. Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Recursion Pharmaceuticals Inc.
    Study site
    University of Pennsylvania
    Registry record
    NCT05552755 · updated
  24. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    858 Therapeutics, Inc.
    Study site
    Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06395519 · updated
  25. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tasca Therapeutics
    Study site
    University of Pennsylvania
    Registry record
    NCT07030257 · updated
  26. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Clasp Therapeutics, Inc.
    Study sites
    Fox Chase Cancer Center · Thomas Jefferson University, Sidney Kimmel Cancer Center
    Registry record
    NCT06778863 · updated
  27. Adaptive Radiation Boost for Rectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Fox Chase Cancer Center
    Study site
    Fox Chase Cancer Center
    Registry record
    NCT07221058 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Ask about studies near Philadelphia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call